This story originally ran on Aug. 18.
By Adam Bonislawski
Diagnostics firm Clarient said last week that it has received US and European patents for its Mammostrat breast cancer test, which it plans to release in the US later this year.
The company is completing clinical validation and assay development and training its sales force in preparation for a Q4 launch of the protein biomarker-based diagnostic, Clarient senior vice president of technology Rob Seitz told ProteoMonitor.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
